Cargando…

An overview of some potential immunotherapeutic options against COVID-19

After the advent of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) in the late 2019, the resulting severe and pernicious syndrome (COVID-19) immediately was deployed all around the world. To date, despite relentless efforts to control the disease by drug repurposing, there is...

Descripción completa

Detalles Bibliográficos
Autores principales: Bayat, Maryam, Asemani, Yahya, Mohammadi, Mohammad Reza, Sanaei, Mahsa, Namvarpour, Mozhdeh, Eftekhari, Reyhaneh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908848/
https://www.ncbi.nlm.nih.gov/pubmed/33765610
http://dx.doi.org/10.1016/j.intimp.2021.107516
_version_ 1783655800687820800
author Bayat, Maryam
Asemani, Yahya
Mohammadi, Mohammad Reza
Sanaei, Mahsa
Namvarpour, Mozhdeh
Eftekhari, Reyhaneh
author_facet Bayat, Maryam
Asemani, Yahya
Mohammadi, Mohammad Reza
Sanaei, Mahsa
Namvarpour, Mozhdeh
Eftekhari, Reyhaneh
author_sort Bayat, Maryam
collection PubMed
description After the advent of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) in the late 2019, the resulting severe and pernicious syndrome (COVID-19) immediately was deployed all around the world. To date, despite relentless efforts to control the disease by drug repurposing, there is no approved specific therapy for COVID-19. Given the role of innate and acquired immune components in the control and elimination of viral infections and inflammatory mutilations during SARS-CoV2 pathogenesis, immunotherapeutic strategies appear to be beneficent. Passive immunotherapies such as convalescent plasma, which has received much attention especially in severe cases, as well as suppressing inflammatory cytokines, interferon administration, inhibition of kinases and complement cascade, virus neutralization with key engineered products, cell-based therapies, immunomodulators and anti-inflammatory drugs are among the key immunotherapeutic approaches to deal with COVID-19, which is discussed in this review. Also, details of leading COVID-19 vaccine candidates as the most potent immunotherapy have been provided. However, despite salient improvements, there is still a lack of completely assured vaccines for universal application. Therefore, adopting proper immunotherapies according to the cytokine pattern and involved immune responses, alongside engineered biologics specially ACE2-Fc to curb SARS-CoV2 infection until achieving a tailored vaccine is probably the best strategy to better manage this pandemic. Therefore, gaining knowledge about the mechanism of action, potential targets, as well as the effectiveness of immune-based approaches to confront COVID-19 in the form of a well-ordered review study is highly momentous.
format Online
Article
Text
id pubmed-7908848
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-79088482021-02-26 An overview of some potential immunotherapeutic options against COVID-19 Bayat, Maryam Asemani, Yahya Mohammadi, Mohammad Reza Sanaei, Mahsa Namvarpour, Mozhdeh Eftekhari, Reyhaneh Int Immunopharmacol Review After the advent of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) in the late 2019, the resulting severe and pernicious syndrome (COVID-19) immediately was deployed all around the world. To date, despite relentless efforts to control the disease by drug repurposing, there is no approved specific therapy for COVID-19. Given the role of innate and acquired immune components in the control and elimination of viral infections and inflammatory mutilations during SARS-CoV2 pathogenesis, immunotherapeutic strategies appear to be beneficent. Passive immunotherapies such as convalescent plasma, which has received much attention especially in severe cases, as well as suppressing inflammatory cytokines, interferon administration, inhibition of kinases and complement cascade, virus neutralization with key engineered products, cell-based therapies, immunomodulators and anti-inflammatory drugs are among the key immunotherapeutic approaches to deal with COVID-19, which is discussed in this review. Also, details of leading COVID-19 vaccine candidates as the most potent immunotherapy have been provided. However, despite salient improvements, there is still a lack of completely assured vaccines for universal application. Therefore, adopting proper immunotherapies according to the cytokine pattern and involved immune responses, alongside engineered biologics specially ACE2-Fc to curb SARS-CoV2 infection until achieving a tailored vaccine is probably the best strategy to better manage this pandemic. Therefore, gaining knowledge about the mechanism of action, potential targets, as well as the effectiveness of immune-based approaches to confront COVID-19 in the form of a well-ordered review study is highly momentous. Elsevier B.V. 2021-06 2021-02-26 /pmc/articles/PMC7908848/ /pubmed/33765610 http://dx.doi.org/10.1016/j.intimp.2021.107516 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
Bayat, Maryam
Asemani, Yahya
Mohammadi, Mohammad Reza
Sanaei, Mahsa
Namvarpour, Mozhdeh
Eftekhari, Reyhaneh
An overview of some potential immunotherapeutic options against COVID-19
title An overview of some potential immunotherapeutic options against COVID-19
title_full An overview of some potential immunotherapeutic options against COVID-19
title_fullStr An overview of some potential immunotherapeutic options against COVID-19
title_full_unstemmed An overview of some potential immunotherapeutic options against COVID-19
title_short An overview of some potential immunotherapeutic options against COVID-19
title_sort overview of some potential immunotherapeutic options against covid-19
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908848/
https://www.ncbi.nlm.nih.gov/pubmed/33765610
http://dx.doi.org/10.1016/j.intimp.2021.107516
work_keys_str_mv AT bayatmaryam anoverviewofsomepotentialimmunotherapeuticoptionsagainstcovid19
AT asemaniyahya anoverviewofsomepotentialimmunotherapeuticoptionsagainstcovid19
AT mohammadimohammadreza anoverviewofsomepotentialimmunotherapeuticoptionsagainstcovid19
AT sanaeimahsa anoverviewofsomepotentialimmunotherapeuticoptionsagainstcovid19
AT namvarpourmozhdeh anoverviewofsomepotentialimmunotherapeuticoptionsagainstcovid19
AT eftekharireyhaneh anoverviewofsomepotentialimmunotherapeuticoptionsagainstcovid19
AT bayatmaryam overviewofsomepotentialimmunotherapeuticoptionsagainstcovid19
AT asemaniyahya overviewofsomepotentialimmunotherapeuticoptionsagainstcovid19
AT mohammadimohammadreza overviewofsomepotentialimmunotherapeuticoptionsagainstcovid19
AT sanaeimahsa overviewofsomepotentialimmunotherapeuticoptionsagainstcovid19
AT namvarpourmozhdeh overviewofsomepotentialimmunotherapeuticoptionsagainstcovid19
AT eftekharireyhaneh overviewofsomepotentialimmunotherapeuticoptionsagainstcovid19